Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | LATS1 | O95835 | 2/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL504843 | 1.00 | CYP3A4 (0.44) | CYP3A4TDP1CSNK2A2CSNK2A1MAOA | |
| SCHEMBL7684354 | 1.00 | CYP3A4 (0.44) | CYP3A4TDP1CSNK2A2CSNK2A1MAOA | |
| SCHEMBL7262254 | 1.00 | CYP3A4 (0.44) | CYP3A4TDP1CSNK2A2CSNK2A1MAOA | |
| SCHEMBL6949196 | 1.00 | CYP3A4 (0.44) | CYP3A4TDP1CSNK2A2CSNK2A1MAOA | |
| SCHEMBL7256799 | 0.87 | MAPKAPK2 (0.41) | CYP3A4TDP1CSNK2A2CSNK2A1MAOA | |
| SCHEMBL7256797 | 0.87 | MAPKAPK2 (0.41) | CYP3A4TDP1CSNK2A2CSNK2A1MAOA | |
| SCHEMBL7262252 | 0.83 | ACHE (0.44) | — | |
| SCHEMBL7681578 | 0.82 | CYP3A4 (0.42) | CYP3A4TDP1MAOAMAOBCA12 | |
| SCHEMBL7681587 | 0.82 | CYP3A4 (0.42) | CYP3A4TDP1MAOAMAOBCA12 | |
| SCHEMBL7261280 | 0.82 | TDP1 (0.39) | CYP3A4TDP1MAOAMAOBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029036-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TIANJIN MICHELE SCI-TECH DEVELOPMENT CO., LTD. (CN) | 2012-02-02 | — | — | US | claimed |
| EP-2394649-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDYL CYANOGUANIDINES, PREPARATION METHODS AND USES THEREOF | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2011-12-14 | — | — | EP | claimed |
| EP-1411984-B1 | COMBINATION MEDICAMENT FOR TREATMENT OF NEOPLASTIC DISEASES WHICH CONTAINS CYANOGUANIDINE IKK INHIBITORS AND A SECOND ANTI-NEOPLASTIC DRUG | LEO PHARMA AS (DK) | 2008-05-07 | — | — | EP | claimed |
| EP-2894149-B1 | Cyanoguanidine prodrugs | LEO PHARMA AS (DK) | 2017-08-02 | — | — | EP | disclosed |
| EP-1339686-B1 | CYANOGUANIDINE PRODRUGS | LEO PHARMA AS (DK) | 2015-09-16 | — | — | EP | disclosed |
| EP-2894149-A1 | Cyanoguanidine prodrugs | LEO PHARMA A/S (DK) | 2015-07-15 | — | — | EP | disclosed |
| US-20120029036-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TIANJIN MICHELE SCI-TECH DEVELOPMENT CO., LTD. (CN) | 2012-02-02 | — | — | US | disclosed |
| EP-2394649-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDYL CYANOGUANIDINES, PREPARATION METHODS AND USES THEREOF | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2011-12-14 | — | — | EP | disclosed |
| US-20050075341-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | PHARMACIA CORPORATION (US) | 2005-04-07 | — | — | US | disclosed |
| US-6525077-B2 | Antiproliferative agents | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-02-25 | — | — | US | disclosed |
| US-20020165201-A1 | Cyanoguanidine prodrugs | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165201-A1 | Cyanoguanidine prodrugs | CBR1, SIGMAR1, ROR1 | CYP3A4 175/4885TDP1 2624/4885CSNK2A2 1321/4885 |
| US-20120029036-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF | PLPBP, PYGL, QDPR | CYP3A4 117/4885TDP1 2081/4885CSNK2A2 178/4885 |
| US-20050075341-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | IKBKE, IKBKG, IKBKB | CYP3A4 4556/4885TDP1 576/4885CSNK2A2 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.